Arvind Sood

Head of Investor Relations

Equibles does not estimate personal net worth.

Get an email with a short summary when Innate Pharma SA publishes a filing, an earnings call transcript or a press release.

Get IPHA alerts

About Arvind Sood

Arvind Sood is recorded as Head of Investor Relations at Amgen Inc (AMGN). Arvind Sood has spoken on 12 earnings calls across 1 company, most recently for Amgen Inc on April 8, 2026. Amgen Inc is classified in the Drug Manufacturers - General industry within the Healthcare sector. Innate Pharma SA is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Amgen Inc includes Robert Bradway (CEO), David W. Meline (CFO), Thomas Dittrich (CFO) and 7 others.

Arvind Sood on recent calls

“We'll leave the call today and be followed by a broader review of our performance, Jay Bradner and Peter Griffith. Today, performance, and I've provided over to you, Bob.”

Head of Investor Relations, Amgen Inc Q2 FY2026 Earnings Call · April 8, 2026

“Good afternoon, everyone, and welcome to our call to discuss our results for the second quarter. We continued down the path of strong unit volume growth during the quarter that led to an improved outlook for the rest of the year.”

Head of Investor Relations, Amgen Inc Q2 FY2023 Earnings Call · August 3, 2023

“Good afternoon, everyone, and welcome to our call to discuss our results for the first quarter of 2023. Strong unit volume growth that sets up the stage nicely for improved outlook for the balance of the year.”

Head of Investor Relations, Amgen Inc Q1 FY2023 Earnings Call · April 27, 2023

“Good afternoon, everyone and welcome to our call to discuss the results for Q4 and the full year 2022. 2022 was once again a year exemplified by great execution despite some of the macro challenges.”

Head of Investor Relations, Amgen Inc Q4 FY2022 Earnings Call · January 31, 2023

“So we continued with our execution during the quarter with a focus on driving volume growth for our key products and advancing our innovative pipeline. Leading the discussion today will be our Chairman and CEO, Bob Bradway.”

Head of Investor Relations, Amgen Inc Q3 FY2022 Earnings Call · November 3, 2022